More recently, Lilly reported topline phase 3 TRIUMPH-1 results in adults with obesity or overweight without diabetes
10.2337/diab.46.9.1440 Diabetes 95 TalbotK.WantH.-Y.KaziH.BennettD.TrojanowskiJ
Tirzepatide (Mounjaro / Zepbound) A dual GLP-1 and GIP agonist, tirzepatide often produces greater weight loss than Semaglutide (1522.5% vs 1215% in clinical trials)
Bariatric surgery represents the most effective long-term intervention for severe obesity, with sustained weight loss and metabolic improvements exceeding those achieved with medications alone
In addition to being a GLP-1 medication, it has a second component known as GIP, or gastric inhibitory polypeptide
Although choices of stroke treatment remain limited, much advance have been achieved in assisting patients in recovering from ischemic stroke, along with progress of recanalization therapy through pharmacological and mechanical thrombolysis